Education
About Us
Working with TipRanks
Follow Us
Avidity Biosciences Inc (RNA)
:RNA
RNA Analyst Ratings
Moderate Buy
5 Buy
10 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
RNA Stock 12 Month Forecast
Average Price Target
$71.71
▲(1.26% Upside)
| Highest Price Target$96.00 | Average Price Target$71.71 | Lowest Price Target$53.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Wells Fargo
$75
Buy
5.90%
Upside
Reiterated
11/13/25
Citi
$72
Hold
1.67%
Upside
Reiterated
11/12/25
TD Cowen
$74
Hold
4.49%
Upside
Reiterated
11/11/25
Needham
―
Hold
―
Reiterated
11/11/25
RBC Capital
$72
Hold
1.67%
Upside
Reiterated
11/10/25
Chardan Capital
$72
Hold
1.67%
Upside
Reiterated
11/07/25
Leerink Partners
$65→$72
Hold
1.67%
Upside
Downgraded
10/27/25
H.C. Wainwright
$87→$72
Hold
1.67%
Upside
Downgraded
10/27/25
Raymond James
$72
Hold
1.67%
Upside
Downgraded
10/27/25
Avidity Biosciences (RNA) was downgraded to a Hold Rating at Raymond JamesWe view NVS as a logical buyer for RNA given their presence in neuroscience and rare neuromuscular markets (i.e., SMA gene therapy Zolgensma). As Avidity approaches multiple potentially registrational data readouts (Ph3 HARBOR in DM1, Ph2 FORTITUDE in FSHD) and BLA submissions (del-zota in DMD, del-desiran in DM1, and del-brax in FSHD) in 2026, we think an established player like NVS will be able to help maximize the commercial potential of these assets globally. We don’t anticipate substantial regulatory risk surrounding this acquisition, as all three of the acquired assets are poised to be the first approved products in their disease indication and none of NVS’ clinical pipeline programs target the RNA program indications.
Bernstein
$52→$72
Hold
1.67%
Upside
Downgraded
10/27/25
Roth MKM
$62→$72
Hold
1.67%
Upside
Downgraded
10/27/25
Bank of America Securities
$65
Buy
-8.22%
Downside
Reiterated
10/13/25
Avidity Biosciences: Strategic Progress and Promising Clinical Data Drive Buy RatingWe agree and highlight the recent del-zota OLE data confirming that the robust increases in dystrophin production demonstrated at the phase 1/2 topline led to clinically meaningful improvements on several key functional endpoints (see our 9/10 note). We currently assign the program a 75% LoS and model peak risk-adjusted sales of $366mn (late-2026 launch). We highlight 2026 will be a pivotal year for RNA as the DMD 1Q26 filing will be the first of 3 potential approval filings as RNA guides to registrational data in DM1 and FSHD in 2Q26 (potential filings in 2H26). We reiterate our Buy rating with $65 PO as we continue to have a bullish view on pipeline opportunity. DM1 and FSHD data in 2Q26 to support 2H26 filings RNA maintains guidance to topline DM1 and FSHD data in 2Q26.
Evercore ISI
$70→$65
Buy
-8.22%
Downside
Reiterated
09/22/25
Cantor Fitzgerald
$96
Buy
35.55%
Upside
Reiterated
09/10/25
Goldman Sachs
$53
Buy
-25.16%
Downside
Assigned
09/10/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Wells Fargo
$75
Buy
5.90%
Upside
Reiterated
11/13/25
Citi
$72
Hold
1.67%
Upside
Reiterated
11/12/25
TD Cowen
$74
Hold
4.49%
Upside
Reiterated
11/11/25
Needham
―
Hold
―
Reiterated
11/11/25
RBC Capital
$72
Hold
1.67%
Upside
Reiterated
11/10/25
Chardan Capital
$72
Hold
1.67%
Upside
Reiterated
11/07/25
Leerink Partners
$65→$72
Hold
1.67%
Upside
Downgraded
10/27/25
H.C. Wainwright
$87→$72
Hold
1.67%
Upside
Downgraded
10/27/25
Raymond James
$72
Hold
1.67%
Upside
Downgraded
10/27/25
Avidity Biosciences (RNA) was downgraded to a Hold Rating at Raymond JamesWe view NVS as a logical buyer for RNA given their presence in neuroscience and rare neuromuscular markets (i.e., SMA gene therapy Zolgensma). As Avidity approaches multiple potentially registrational data readouts (Ph3 HARBOR in DM1, Ph2 FORTITUDE in FSHD) and BLA submissions (del-zota in DMD, del-desiran in DM1, and del-brax in FSHD) in 2026, we think an established player like NVS will be able to help maximize the commercial potential of these assets globally. We don’t anticipate substantial regulatory risk surrounding this acquisition, as all three of the acquired assets are poised to be the first approved products in their disease indication and none of NVS’ clinical pipeline programs target the RNA program indications.
Bernstein
$52→$72
Hold
1.67%
Upside
Downgraded
10/27/25
Roth MKM
$62→$72
Hold
1.67%
Upside
Downgraded
10/27/25
Bank of America Securities
$65
Buy
-8.22%
Downside
Reiterated
10/13/25
Avidity Biosciences: Strategic Progress and Promising Clinical Data Drive Buy RatingWe agree and highlight the recent del-zota OLE data confirming that the robust increases in dystrophin production demonstrated at the phase 1/2 topline led to clinically meaningful improvements on several key functional endpoints (see our 9/10 note). We currently assign the program a 75% LoS and model peak risk-adjusted sales of $366mn (late-2026 launch). We highlight 2026 will be a pivotal year for RNA as the DMD 1Q26 filing will be the first of 3 potential approval filings as RNA guides to registrational data in DM1 and FSHD in 2Q26 (potential filings in 2H26). We reiterate our Buy rating with $65 PO as we continue to have a bullish view on pipeline opportunity. DM1 and FSHD data in 2Q26 to support 2H26 filings RNA maintains guidance to topline DM1 and FSHD data in 2Q26.
Evercore ISI
$70→$65
Buy
-8.22%
Downside
Reiterated
09/22/25
Cantor Fitzgerald
$96
Buy
35.55%
Upside
Reiterated
09/10/25
Goldman Sachs
$53
Buy
-25.16%
Downside
Assigned
09/10/25
Best Analysts Covering Avidity Biosciences
1 Month
xxx
Success Rate
17/27 ratings generated profit
Average Return
+7.24%
reiterated a xxx
rating 22 hours ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 62.96% of your transactions generating a profit, with an average return of +7.24% per trade.
3 Months
xxx
Success Rate
7/11 ratings generated profit
Average Return
+22.22%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +22.22% per trade.
1 Year
Success Rate
11/11 ratings generated profit
Average Return
+83.30%
reiterated a buy rating last month
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +83.30% per trade.
2 Years
xxx
Success Rate
11/11 ratings generated profit
Average Return
+87.94%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +87.94% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
RNA Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
34
28
15
13
9
Buy
1
11
15
18
8
Hold
11
11
13
20
22
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
46
50
43
51
39
Each month's total comprises the sum of three months' worth of ratings.
RNA Financial Forecast
RNA Stock Forecast FAQ
What is RNA’s average 12-month price target, according to analysts?
Based on analyst ratings, Avidity Biosciences Inc’s 12-month average price target is 71.71.
What is RNA’s upside potential, based on the analysts’ average price target?
Avidity Biosciences Inc has 1.26% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is RNA a Buy, Sell or Hold?
Avidity Biosciences Inc has a consensus rating of Moderate Buy which is based on 5 buy ratings, 10 hold ratings and 0 sell ratings.
What is Avidity Biosciences Inc’s price target?
The average price target for Avidity Biosciences Inc is 71.71. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $96.00 ,the lowest forecast is $53.00. The average price target represents 1.26% Increase from the current price of $70.82.
The highest analyst price target is $96.00 ,the lowest forecast is $53.00. The average price target represents 1.26% Increase from the current price of $70.82.
What do analysts say about Avidity Biosciences Inc?
Avidity Biosciences Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.
How can I buy shares of RNA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.